CEPI and Samsung Biologics have teamed up to improve vaccine production for future disease outbreaks as well as make sure people in all countries can get them. The goal is to create a faster and more efficient way to produce protein-based vaccines, especially for low- and middle-income countries that need them most.
With an initial budget of up to USD 20 million, they will set up a system to quickly make vaccines using Samsung Biologics' proven technology. This system will allow vaccines to be made quickly when a new virus appears.
Samsung Biologics will also run a practice exercise using the H5 flu virus to test how quickly vaccines can be produced in an emergency. This will help ensure that vaccines can be made at a large scale and in a short time.
By joining CEPI’s network, Samsung Biologics will guarantee that up to 50 million vaccine doses are available in case of a future pandemic. They will also make sure there are extra doses ready to help other countries that need them.
As the partnership grows, there may be more projects to improve vaccine technology and preparedness for future outbreaks.
Executive Statement
According to John Rim, President and CEO of Samsung Biologics, this agreement reflects their commitment to supporting a reliable and agile vaccine supply ecosystem through continued innovation and strong collaboration. It also contributes to Korea's ability to secure timely access to vaccines during urgent public-health situations. By operating with CEPI to advance recombinant protein vaccine development and ensure capacity for timely production when demand rises, they aim to broaden access to high-quality vaccines for patients around the world. Samsung Biologics will continue to apply its technical and vaccine manufacturing expertise to strengthen global preparedness and help build a more resilient response environment.
